For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
Selank
Cognitive & Anxiolytic Peptide
Dosage
Quantity
Price
$26.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- Selank 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from tuftsin with extensive Russian-language clinical literature and limited Western registration. This block summarizes published human and preclinical themes for education only—not medical advice or an FDA-approved use statement for this SKU.
Similar
Anxiolytic signal
RCT narratives describe anxiety-score improvements in the same range as benzodiazepine comparators (e.g., medazepam).
BDNF ↑
Neuroprotection
Preclinical reports link Selank to BDNF preservation or upregulation in stress and ethanol models.
92.8%
Bioavailability
Intranasal pharmacokinetic summaries quote high fractional absorption vs parent peptide benchmarks.
No BZD-like
Dependence profile
Trial summaries emphasize absence of sedation, amnesia, and withdrawal syndromes typical of benzodiazepines.
7 aa
Heptapeptide
Sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), tuftsin-extended scaffold.
Development status
Regulatory context
Developed at the Institute of Molecular Genetics (Russian Academy of Sciences) with clinical collaborators (e.g., Zakusov Institute). Marketed as prescription intranasal drops in some jurisdictions—not cleared by FDA for any indication in the United States.
- Developer
- Russian Academy of Sciences (IMG)
- Collaborator
- V.V. Zakusov Institute (cited in reviews)
- Approval (selected)
- Russia (2009), Ukraine (GAD)
- US status
- Not FDA-approved
- Rx formulation (RU)
- 0.15% nasal drops (per national labels)
What research has shown
Human trials and preclinical extensions cited in reviews
Randomized controlled trials
62
Patients — GAD / neurasthenia vs medazepam (published series)
Psychometric improvement (Hamilton / Zung / CGI narratives)
Both arms showed similar anxiolysis in summarized trials; Selank was additionally described with anti-asthenic / mild psychostimulant qualities in some clinician reports.
Read primary Russian clinical manuscripts for scale definitions.
Clinical outcomes
Safety & efficacy themes
Beyond anxiety relief
Multi-system motifs from reviews
BDNF
Neuroprotection
Plasticity and stress-resilience framing in animal work.
IL-6
Immune support
Cytokine modulation alongside tuftsin-like biology.
0%
Cognitive impairment
Trials emphasize preserved vigilance vs classic sedative anxiolytics.
ENK
Stress resilience
Enkephalin-degrading enzyme inhibition discussed in mechanistic papers.
Cognitive enhancement
Nootropic narratives
Reviews tie Selank to memory consolidation, attention, and learning alongside BDNF and monoamine balance—not a stimulant replacement in trial language.
- Memory↑ discussed
- Attention↑ discussed
- Learning↑ discussed
- Focus↑ variable
Dual action: anxiolysis without the cognitive dulling often attributed to classical benzodiazepines in comparative discussions.
Stress response
Adaptive regulation
Clinical and preclinical summaries describe improved stress tolerance with preserved daytime alertness—figures below are illustrative review scales, not universal effect sizes.
Immune function
Tuftsin-analog biology
As a tuftsin derivative, Selank inherits immunomodulatory discussion: cytokine shifts, interferon tone, and innate-cell activity in experimental settings.
- IL-6Modulated
- TNF-α↓ in models
- Interferons↑ discussed
- TGF-β1Normalized in some reports
Neuroprotection
BDNF in ethanol models
Rodent ethanol protocols report protection of hippocampal and prefrontal BDNF expression when Selank is present—model- specific, not a human outcome claim.
BDNF
Preserved vs ethanol-induced suppression in cited brain regions
Research finding: Selank prevented ethanol-linked BDNF depression in hippocampus and PFC in published preclinical summaries.
Safety profile from research
Intranasal clinical experience (summaries)
Russian trial compendia emphasize high tolerability, lack of sedation or amnesia, and absence of benzodiazepine-like dependence or withdrawal in monitored courses.
Frequently reported mild events
Nasal irritation
MildMild headache
MildVivid dreams
MildThroat irritation
MildNon-sedating anxiolysis narrative
Comparative reviews contrast Selank with benzodiazepines on sedation, muscle relaxation, anterograde amnesia, tolerance, and withdrawal.
- No meaningful sedation or daytime somnolence in summarized trials
- No amnesia / cognitive blunting pattern described like high-dose BZDs
- No physical dependence signal in available clinical disclosures
- No withdrawal syndrome on abrupt cessation in those reports
Discontinuation themes
- GAD programsExcellent tolerability
- Combination with diazepamNo excess AE signal in cited work
- Repeat dosingNo tolerance narrative in summaries
- Dependence not observed in published Russian trial sets reviewed here.
- Withdrawal symptoms not described on stop.
- Peptide hydrolyzes to natural amino acids—metabolic fate often cited for safety rationale.
Planning flags
- Registered anxiolytic in Russia (2009) and Ukraine per national drug registers—not a US approval.
- Most jurisdictions treat research-grade material as non-approved for human therapeutic marketing.
- 0.15% nasal drops require a prescription where legally sold as a medicine.
Storage handling reference
Peptide handling
Cold
Lyophilized: store per COA.
Reconstitution
Sterile technique if injecting; intranasal ≠ this SKU.
Light
Protect during prep.
Documentation
Log batch and route of use in studies.
Researcher notes
- Safety narrative is strongest relative to benzodiazepines in the literature that directly compares them—context matters.
- Metabolic breakdown to amino acids is a common justification for tolerability; it does not remove all interaction risks.
- Most adverse events in registries are mild, local (nasal), and transient.
- Clinical use in Russia since 2009 informs post-market experience, but US researchers should default to local regulations.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.